pyrimidinones and Peptic-Ulcer

Topics: Breath Tests; Carbon Isotopes; False Negative Reactions; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors; Pyrimidinones; Tetrahydroisoquinolines; Urea

Revaprazan (Revanex(R)) is a novel proton pump inhibitor (PPI) that has a somewhat different effect on proton pump compared with the other PPI's, also (called as 'acid pump antagonist'). We aimed to examine the false negative rate of 13C-urea breath test (UBT) in the patients with Helicobacter pylori (H. pylori) associated peptic ulcer disease who were treated with revaprazan and evaluate the anti-urease activity of revaprazan.. Total 55 patients were enrolled in this study. They received EGD examination between January 2009 and December 2009 and diagnosed histologically as H. pylori associated peptic ulcer disease. All patients took revaprazan only. Three patients were excluded because of underlying chronic disease and inappropriate breath sampling. The remaining 52 patients had UBT at 0, 2 and 4 weeks of revaprazan use. After 2 weeks of the cessation of revaprazan, they had the fourth UBT.. At 2 and 4 weeks, the false negative rates of UBT were 5.8% and 23.1%, respectively (p=0.05). After 2 weeks of the cessation, the cases of the false negative result were five. Four out of five patients had prolonged negative results on two or three successive tests, and baseline 13C difference value did not predict the false negative results.. False negative results of UBT were common and increased with prolonged use of acid pump antagonist. As PPI, it had also anti-urease activity and most patients (47/52, 90.4%) reverted to positive results by 2 weeks after the cessation of taking the medication.

Topics: Breath Tests; Carbon Isotopes; False Negative Reactions; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyrimidinones; Tetrahydroisoquinolines; Urea

Single doses of 10 mg or 20 mg intravenously or 25 mg or 40 mg orally of a new histamine H2-receptor antagonist, SK&F 93479, have been administered to 31 patients with peptic ulcer disease. BAO and MAO were measured before and repeated during a 26-h period after drug administration. In a separate group of 17 patients the mean coefficients of variation of BAO and MAO measured in this manner were 53% and 20%, respectively. If this variation in the placebo group is taken into account, BAO was significantly inhibited at all dose levels during the 3rd h after dosing, and a significant effect was still seen during the 25th h after 40 mg orally with a mean reduction of 77%. Mean inhibitions of MAO during the 4th h after dosing of SK&F 93479 were significant at all dose levels, and a significant effect could still be seen during the 26th h for the two oral doses. The mean inhibitions of MAO measured during the 4th and 10th h after dosing were after 10 mg intravenously 44% and 11%, after 20 mg intravenously 59% and 11%, after 25 mg orally 57% and 21%, and after 40 mg orally 75% and 46%. The percentage inhibition of MAO during the 10th h correlated with plasma concentrations (r = 0.64, p less than 0.01). SK&F 93479 is a potent inhibitor of acid secretion with a long duration of action.

Topics: Administration, Oral; Adult; Aged; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Injections, Intravenous; Male; Middle Aged; Pentagastrin; Peptic Ulcer; Pyrimidinones

The toxic side-effects and anti-inflammatory activity of combination treatment of Sprague-Dawley rats with indomethacin and Probon, a new type of analgesic, were investigated. Following four weeks of treatment with a combination of these two drugs, the characteristic gastrointestinal side-effect of indomethacin was markedly reduced. Mortality resulting from administration of the drug combination was significantly lower than that resulting from indomethacin treatment alone. The reduced toxicity of indomethacin in combination with Probon is probably due to a change in metabolism produced by the hepatic microsomal enzyme inducer, Probon. The anti-inflammatory effect was also investigated using a contact thermographic method following one, three or seven days pretreatment. The advantage of this combination is that, using a higher dose of indomethacin in combination with the minor analgesic, we could achieve a more reliable anti-inflammatory effect together with a pain-killing action.

Topics: Animals; Antipyrine; Drug Interactions; Drug Therapy, Combination; Female; Indomethacin; Male; Peptic Ulcer; Pyrimidinones; Rats; Rats, Inbred Strains